Niti Aayog Urges Pharma Industry to Ramp Up Research and Development Spending
Niti Aayog warns that India's pharmaceutical sector must increase R&D investment and address regulatory bottlenecks to transition from generic manufacturing to high-value segments like biologics and advanced therapies, warning against continued over-reliance on imported components and outdated infrastructure.
Highlights
- •Niti Aayog identifies R&D investment gaps as a barrier to high-value pharma growth.
- •Indian firms invest roughly 7% of net sales in R&D, compared to 15-20% by global peers.
- •Report highlights heavy reliance on Chinese imports for APIs despite local production initiatives.
- •Policy recommendations include better IP predictability and strengthening industry-academia research links.
The Niti Aayog has issued a significant advisory urging domestic pharmaceutical firms to substantially boost their investments in research and development. In a recent analysis, the policy think tank expressed concerns that existing vulnerabilities in the national innovation ecosystem, coupled with various regulatory hurdles, could potentially stall India's progress in evolving from a global hub for generic medicines into a leader in high-value pharmaceutical sectors, such as biologics, biosimilars, vaccines, and advanced therapeutic solutions.
According to the latest Trade Watch report, while India maintains a strong presence in the global market through volume-driven generic drugs, its engagement with more sophisticated, high-growth segments remains notably limited. The report identifies several critical barriers, including the heavy capital investment required for bio-manufacturing facilities and the long, resource-intensive gestation periods inherent in drug development.
Addressing Structural Challenges in Pharmaceutical R&D
A primary concern highlighted by the Niti Aayog is the disparity in investment levels. Currently, Indian pharmaceutical entities allocate approximately seven percent of their net sales toward R&D, a figure that significantly trails the 15 to 20 percent investment levels maintained by international competitors. Furthermore, the development cycle for new drugs typically spans 10 to 15 years, requiring sustained financial commitment.
The report also sheds light on structural constraints that act as deterrents to long-term growth. Frequent pre-grant oppositions and a lack of clarity regarding disposal timelines create an environment of uncertainty for innovators regarding patent grants. Additionally, the existing weakness in industry-academia partnerships and limited technology transfer protocols further hinder the commercialization of public sector research.
The document also notes a persistent reliance on imports for essential components, specifically fermentation-based APIs and key intermediates sourced from China. This dependence remains despite existing domestic capacity and the implementation of the Production Linked Incentive (PLI) scheme, which was originally intended to bolster local manufacturing capabilities.
Regulatory and Compliance Hurdles
Beyond internal R&D limitations, the sector faces substantial pressure from international trade frictions and domestic compliance costs. The Trade Watch report identifies several non-tariff barriers in key export markets, such as complex registration processes, redundant inspections, and strict documentation requirements. These challenges prove especially burdensome for MSME exporters.
Moreover, the cost of meeting rigorous environmental standards—such as Central Pollution Control Board (CPCB) norms, zero liquid discharge requirements, and effluent-treatment mandates—has risen sharply. To overcome these obstacles, the agency suggests proactive policy diversification, the strengthening of public-private partnerships, and the adoption of time-bound processes for patent opposition. These measures are viewed as vital steps for India to secure a more prominent position in the high-value global pharmaceutical industry.
,curated_key_highlights:[
